This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart 30 as start insulin in subjects with type 2 diabetes failing OAD therapy.

Inclusion Criteria:

• Type 2 diabetes for at least 24 months
• BMI between 18 and 30 kg/m2
• Insulin naive subjects
• OAD treatment with max two OADs alone or combined with other therapy
• HbA1c between 7-12%

Exclusion Criteria:

• Type 1 diabetes
• Receipt of any investigational drug within the last three months prior to this trial
• Current or previous treatment with thiazolidiones within the last 6 months
• OAD treatment with three or more OADs within the last 4 months